20.500.12556/DiRROS-27797 Real-world experience in treatment of patients with non-small-cell lung cancer with BRAF or cMET exon 14 skipping mutations BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83). non-small-cell lung cancer BRAF V600 mutation cMET exon 14 skipping mutation real-world data targeted therapy first-line therapy nedrobnocelični pljučni rak mutacija BRAF V600 podatki iz resničnega življenja tarčna terapija zdravljenje prvega reda true false true MDPI, 2000- International journal of molecular sciences Angleški jezik Slovenski jezik © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Neznano 2026-02-25 09:34:46 2026-02-25 09:34:46 2026-02-26 03:55:12 0000-00-00 00:00:00 2023 0 0 Nasl. z nasl. zaslona; Opis vira z dne 30. 8. 2023; str. 1-14 iss. 16, [article no.] 12840 Vol. 24 [in press] 2023 0000-00-00 Zaloznikova Objavljeno apc 2023-07-15 2023-08-15 2023-08-16 616-006 1422-0067 10.3390/ijms241612840 162782979 https://www.mdpi.com/1422-0067/24/16/12840 1 d842aac4-1224-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40867 RAZ_Janzic_Urska_2023.pdf RAZ_Janzic_Urska_2023.pdf 1 CCADBE3C202C141A3B5DB28BD854F986 4bb0df39f15b3c069c74530213eb5f600bd0547a311a5ef8ace2191b5819d76e 55218a75-1225-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40869 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0